Considering the pivotal role of immune checkpoints in tumor immunotherapy, we checked the expression of immune checkpoints level in both groups and observed the low-risk group exhibited significantly higher expression levels of LGALS9, CD274, CD48, and TNFRSF14 compared to the high-risk group, indicating that the low-risk group could potentially be more responsive to immune checkpoint blockade (Figure 6C). This evidence concerns the gene CD48 and neoplasm.